Google SSO gives you the quickest path into the IIPLA newsroom, your reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.
On April 21, 2026, China’s Supreme People’s Court (SPC) published its Annual Report on Legal Application Issues in Intellectual Property Cases of Courts Nationwide (2025) (全国法院知识产…
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
On February 24, 2022, the Delhi High Court Intellectual Property Rights Division Rules, 2022 and the High Court of Delhi Rules Governing Patent Suits, 2022 were published in the Official Gazette. All IPR lawsuits, cases, procedures, or disputes before the IPD of the Delhi High Court are subject to the Rules. According…
Universiti Kebangsaan Malaysia (UKM) has been awarded the silver medal in the Best Intellectual Property Management category at the 2026 National Intellectual Property Awards (AHIN), organized by the Intellectual Property Corporation of Malaysia (MyIPO). UKM was the only higher education institution to reach the final…
Stayble Therapeutics AB, a Swedish biotechnology company specializing in injectable treatments for chronic back pain, has called an extraordinary general meeting on May 7 to vote on a proposal for voluntary liquidation. The board's recommendation follows unsuccessful efforts to secure partnerships or financing for its…
A recent report from BakerHostetler underscores the urgent need for US businesses to overhaul their intellectual property strategies in response to the transformative effects of artificial intelligence, evolving social media practices, and significant regulatory changes. The firm’s 2026 IP Perspectives report details…
Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND Charles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes
Biotechnology company Moderna has agreed to pay up to $2.25 billion to settle patent litigation over technology used in its COVID-19 vaccine, resolving a dispute with Arbutus Biopharma and Genevant Sciences. The lawsuits alleged that Moderna’s vaccine relied on patented lipid nanoparticle delivery systems, a technolog…